Clinical Report: Reassessing Empirical Use of Vancomycin in Pediatric Patients

Overview

This study evaluates the necessity and overprescription of empirical vancomycin in pediatric patients in Thailand, where MRSA incidence is low. Findings indicate a significant proportion of patients receiving vancomycin did not require it as definitive therapy, highlighting concerns about overuse and potential resistance.

Background

Vancomycin is a critical treatment for drug-resistant Gram-positive infections, particularly in pediatric patients. However, its empirical use is often not aligned with local MRSA prevalence, leading to unnecessary prescriptions and increased risk of resistance. Understanding the appropriateness of vancomycin use is essential for optimizing treatment and minimizing adverse effects.

Data Highlights

No numerical data available in the source material.

Key Findings

• Only 8.3% to 9.6% of S. aureus isolates in Thailand were MRSA during 2020-2022.
• In the U.S., only 11.2% of patients initially treated with empirical vancomycin required it as targeted therapy.
• Over 65% of empirical vancomycin prescriptions in Brazil were found to be inappropriate.
• Guidelines recommend reserving empirical vancomycin for specific risk scenarios, especially in low-MRSA prevalence areas.
• Studies indicate a high rate of inappropriate vancomycin use in pediatric populations globally.

Clinical Implications

Clinicians should reassess the routine use of empirical vancomycin in pediatric patients, particularly in regions with low MRSA prevalence. Adhering to updated guidelines can help reduce unnecessary prescriptions and the risk of developing vancomycin-resistant bacteria.

Conclusion

This study underscores the need for careful evaluation of empirical vancomycin use in pediatric patients, advocating for a more judicious approach based on local epidemiology and clinical guidelines.

References

1. Junior et al., 2007 -- Evaluation of vancomycin prescribing practices in Brazil
2. Libuit et al., 2014 -- Assessment of vancomycin use in febrile neutropenic patients
3. Rattanaumpawan et al., 2006 -- Vancomycin prescribing in Thailand
4. Children's Oncology Group, 2023 -- Guidelines for pediatric febrile neutropenia
5. The Journal of Infectious Diseases — Prediction of Vancomycin Area Under the Curve With Trough Concentrations Only: Performance Evaluation of Pediatric Population Pharmacokinetic Models
6. ASHP/PIDS/SIDP/IDSA Revised Consensus Guideline for Therapeutic Monitoring of Vancomycin
7. Date
8. Antimicrobial Stewardship & Healthcare Epidemiology (2025), 5, e139, 1–5